MedTrace Logo

Study to Evaluate the Mass Babance and Biotransformation of [14C]SHR6390 in Healthy Adult Male Volunteers

NCT04616742 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2021-05-12

No results posted yet for this study

Summary

Study to Evaluate the mass balance and biotransformation of single dose \[14C\]SHR6390 in Chinese healthy adult male volunteers.

Conditions

  • Healthy Adult Male Volunteers

Interventions

DRUG

[14C]SHR6390

Patients will receive single dose of orally \[14C\]SHR6390 on Day 1.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-11
Primary Completion
2021-01-08
Completion
2021-05-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04616742 on ClinicalTrials.gov